|
End-of-day quote
Shenzhen S.E.
30/09/2026
|
5-day change | 1st Jan Change | ||
| 3.650 CNY | +5.19% |
|
+4.29% | +18.89% |
Company Valuation: Harbin Gloria Pharmaceuticals Co., Ltd
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 7,034 | 6,397 | 5,583 | 5,517 | 5,677 | 6,852 |
| Change | - | -9.06% | -12.71% | -1.18% | 2.89% | 20.71% |
| Enterprise Value (EV) 1 | 7,491 | 6,459 | 5,750 | 5,482 | 5,168 | 6,014 |
| Change | - | -13.78% | -10.98% | -4.66% | -5.72% | 16.38% |
| P/E | 17.6x | 142x | -19.2x | 45.9x | 24.2x | 18.2x |
| PBR | 3.81x | 3.38x | 3.42x | 3.32x | 2.91x | 2.99x |
| PEG | - | -1.6x | 0x | -0x | 0.3x | 0.3x |
| Capitalization / Revenue | 2.3x | 2.03x | 1.8x | 2.1x | 2.33x | 3.21x |
| EV / Revenue | 2.45x | 2.05x | 1.85x | 2.09x | 2.12x | 2.82x |
| EV / EBITDA | 4,078x | 25.5x | 26.8x | 19.9x | 16.4x | 18.8x |
| EV / EBIT | -51.8x | 55.8x | 67.2x | 31.9x | 22.9x | 26.1x |
| EV / FCF | 66.4x | 24.8x | 112x | 54.4x | 14.7x | 76.8x |
| FCF Yield | 1.51% | 4.03% | 0.89% | 1.84% | 6.8% | 1.3% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.182 | 0.0205 | -0.1325 | 0.0547 | 0.1029 | 0.1686 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3,055 | 3,145 | 3,108 | 2,626 | 2,441 | 2,135 |
| EBITDA 1 | 1.837 | 253.2 | 214.5 | 275.5 | 315.9 | 319.7 |
| EBIT 1 | -144.7 | 115.7 | 85.61 | 172 | 225.3 | 230.8 |
| Net income 1 | 400 | 45.04 | -291.3 | 120.3 | 232.8 | 376.9 |
| Net Debt 1 | 457 | 62.42 | 166.7 | -35.59 | -508.7 | -838.1 |
| Reference price 2 | 3.200 | 2.910 | 2.540 | 2.510 | 2.490 | 3.070 |
| Nbr of stocks (in thousands) | 2,198,123 | 2,198,123 | 2,198,123 | 2,198,123 | 2,279,750 | 2,232,028 |
| Announcement Date | 4/28/21 A | 4/25/22 A | 4/23/23 A | 4/19/24 A | 4/25/25 A | 4/27/26 A |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 1.21B | ||
| 32.45x | 11.78x | 23.93x | 0.61% | 1,019B | ||
| 28.48x | 6.32x | 17.7x | 2.09% | 617B | ||
| 33.26x | 7.78x | 16.08x | 2.64% | 464B | ||
| 104.98x | 5.87x | 24.89x | 2.36% | 356B | ||
| 18.81x | 4.58x | 11.36x | 2.9% | 333B | ||
| 19.83x | 5.17x | 12.78x | 3.09% | 267B | ||
| 20.02x | 4.17x | 11.86x | 2.13% | 244B | ||
| 25.46x | 6.66x | 11.86x | 2.5% | 218B | ||
| -43.78x | 6.39x | 24.97x | 2.27% | 179B | ||
| Average | 26.61x | 6.52x | 17.27x | 2.29% | 369.84B | |
| Weighted average by Cap. | 31.80x | 7.61x | 18.61x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 002437 Stock
- Valuation Harbin Gloria Pharmaceuticals Co., Ltd
Select your edition
All financial news and data tailored to specific country editions
















